Physician profile
Jacob Templin
NPI 1295149052
$3,231.08
in general payments reported to CMS, 2019-2025
31 companies · $889 in 2025
The $889 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $130 · 2020: $14.48 · 2021: $280 · 2022: $588 · 2023: $575 · 2024: $756 · 2025: $889.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,219.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,219.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $821.03 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Novartis Pharmaceuticals Corporation | $380.41 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $272.82 | 2021-2025 | |
| Pfizer INC. | $264.97 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $226.86 | 2019-2024 | Ofev, Jardiance |
| Astrazeneca Pharmaceuticals LP | $168.76 | 2019-2025 | Airsupra, Breztri |
| Exact Sciences Corporation | $138.44 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Corcept Therapeutics | $99.16 | 2024-2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $88.35 | 2022 | |
| Phathom Pharmaceuticals, INC. | $85.93 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $81.95 | 2021-2025 | Vaxneuvance, Gardasil 9, Capvaxive |
| Sanofi Pasteur INC. | $53.90 | 2019-2022 | |
| Dexcom, INC. | $52.20 | 2024-2025 | Dexcom G6 Transmitter |
| Daiichi Sankyo INC. | $51.05 | 2019-2022 | |
| Glaxosmithkline, LLC. | $41.55 | 2023 | Trelegy Ellipta, Shingrix |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $36.79 | 2023 | Yupelri |
| Lundbeck LLC | $34.14 | 2024 | Rexulti |
| Philips North America LLC | $32.72 | 2024-2025 | Mcot, (Ck4) Mcot |
| Biohaven Pharmaceutical Holding Company LTD. | $28.39 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $28.26 | 2023 | Rexulti |
| Sunovion Pharmaceuticals INC. | $28.19 | 2019-2021 | |
| Astellas Pharma US INC | $27.37 | 2023 | Veozah |
| Biogen, INC. | $26.70 | 2025 | Leqembi |
| Shionogi INC | $24.79 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $24.27 | 2021 | |
| Novo Nordisk INC | $22.12 | 2024 | Rybelsus, Ozempic |
| Lilly USA, LLC | $22.07 | 2025 | Mounjaro, Zepbound |
| Janssen Pharmaceuticals, INC | $19.07 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.96 | 2025 | Caplyta |
| Xeris Pharmaceuticals, INC. | $17.31 | 2025 | Gvoke Hypopen |
| Circassia INC. | $13.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Templin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.